Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4618 Comments
1346 Likes
1
Grimm
Loyal User
2 hours ago
Thatβs some βwowβ energy. β‘
π 198
Reply
2
Verinda
Engaged Reader
5 hours ago
This is exactly what I was looking for last night.
π 95
Reply
3
Iwona
Registered User
1 day ago
As a detail-oriented person, this bothers me.
π 260
Reply
4
Shalaine
Experienced Member
1 day ago
This feels like something shifted slightly.
π 89
Reply
5
Sadique
Loyal User
2 days ago
The risk considerations section is especially valuable.
π 112
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.